From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue | Zendy

Robert L. Cohen | Zendy; Jeff Settleman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue

Author(s) -

Robert L. Cohen,

Jeff Settleman

Publication year - 2014

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2014.05.027

Subject(s) - breast cancer , trastuzumab , precision medicine , malignancy , cancer , personalized medicine , genomics , targeted therapy , biology , oncology , clinical trial , liquid biopsy , computational biology , translational research , companion diagnostic , bioinformatics , medicine , genome , pathology , gene , genetics

Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research